• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Viatris Inc.

    12/6/24 5:20:53 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTRS alert in real time by email
    8-K
    Viatris Inc false 0001792044 0001792044 2024-12-06 2024-12-06

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 6, 2024

     

     

    VIATRIS INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39695   83-4364296

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317

    (Address of Principal Executive Offices)

    Registrant’s telephone number, including area code: (724) 514-1800

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.01 per share   VTRS   The NASDAQ Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.02(e)

    Approval of an amendment to the Viatris Inc. 2020 Stock Incentive Plan.

    On December 6, 2024, Viatris Inc. (“Viatris” or the “Company”) held its 2024 annual meeting of shareholders (the “2024 Annual Meeting”). As further discussed below, at the 2024 Annual Meeting, shareholders of the Company approved an amendment to the Company’s 2020 Stock Incentive Plan (the “2020 Stock Incentive Plan Amendment”). For a description of the 2020 Stock Incentive Plan Amendment, see the Company’s Definitive Proxy Statement on Schedule 14A (File No. 001-39695), filed with the Securities and Exchange Commission on October 25, 2024 (the “Proxy Statement”). A copy of the 2020 Stock Incentive Plan Amendment is attached as Appendix C to such Proxy Statement.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    (a) On December 6, 2024, the Company held its 2024 Annual Meeting to (i) elect twelve director nominees, each to hold office until the 2025 annual meeting of shareholders; (ii) approve, on a non-binding advisory basis, the 2023 compensation of the named executive officers of the Company; (iii) ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; and (iv) approve the 2020 Stock Incentive Plan Amendment to (1) increase the maximum aggregate number of shares of Viatris common stock reserved and available for issuance for awards pursuant to the 2020 Stock Incentive Plan by 49,000,000 shares, subject to adjustment as provided in the Company’s 2020 Stock Incentive Plan, and (2) eliminate an exception to the 12-month minimum vesting requirement for awards granted on an ad hoc basis in order to achieve a specified business objective. With respect to each proposal below, any abstentions and broker non-votes were considered for purposes of establishing a quorum but were not considered to be votes cast and therefore had no effect on the vote on any such proposal.

     

    (b)

    The certified results of the matters voted on at the 2024 Annual Meeting are set forth below.

    Proposal No. 1 - Election of the following twelve director nominees, each to hold office until the 2025 annual meeting of shareholders:

     

    Nominee

       For      Against      Abstain      Broker Non-Votes  

    W. Don Cornwell

         900,964,555        4,460,343        3,834,109        114,954,301  

    JoEllen Lyons Dillon

         737,759,209        167,733,463        3,766,345        114,954,291  

    Elisha Finney

         902,054,026        3,436,873        3,768,120        114,954,291  

    Leo Groothuis

         878,504,023        26,933,798        3,821,197        114,954,291  

    Melina Higgins

         804,442,071        101,065,484        3,751,463        114,954,291  

    James M. Kilts

         840,616,779        64,831,995        3,810,242        114,954,293  

    Harry Korman

         780,276,345        125,203,030        3,779,642        114,954,292  

    Rajiv Malik

         823,760,959        81,491,917        4,006,144        114,954,289  

    Richard Mark

         900,441,821        5,011,531        3,805,662        114,954,295  

    Mark Parrish

         850,985,723        54,462,270        3,811,027        114,954,289  

    Scott A. Smith

         902,081,653        3,373,699        3,803,668        114,954,288  

    Rogério Vivaldi Coelho

         900,799,052        4,645,816        3,814,152        114,954,289  

    Each director nominee was elected to hold office until the 2025 annual meeting of shareholders.

    Proposal No. 2 – Approval, on a non-binding advisory basis, of the 2023 compensation of the named executive officers of the Company:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    445,035,979   458,870,163   5,352,861   114,954,306


    This proposal was not approved, but received 49.23% of votes in favor (thus missing approval by less than 0.80%).

    Proposal No. 3 – Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    962,950,848   54,384,649   6,877,812   N/A

    This proposal was approved.

    Proposal No. 4 – Approval of the 2020 Stock Incentive Plan Amendment:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    872,421,538   31,280,303   5,557,159   114,954,308

    This proposal was approved.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        VIATRIS INC.
    Date: December 6, 2024     By:  

    /s/ Theodora Mistras

          Theodora Mistras
          Chief Financial Officer
    Get the next $VTRS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VTRS

    DatePrice TargetRatingAnalyst
    6/6/2025$10.00Neutral
    Goldman
    7/19/2024$15.00Buy
    Jefferies
    10/23/2023$13.00 → $9.00Neutral → Underperform
    BofA Securities
    6/23/2023$11.00Equal Weight → Underweight
    Barclays
    4/24/2023$11.00Overweight → Equal Weight
    Barclays
    2/17/2023$16.00 → $14.00Outperform → Market Perform
    BMO Capital Markets
    1/27/2023$13.00 → $15.00Hold → Buy
    Jefferies
    11/10/2022$9.00 → $12.00Sell → Neutral
    UBS
    More analyst ratings

    $VTRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

      MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety Profile Consistent With Previous Clinical Trials And No Treatment-Related Serious Adverse Events Reported In This Study Targeting Application To U.S. FDA In Second Half of 2025 PITTSBURGH, June 26, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) in treating presbyopia. Presbyopia is the progressive loss of the ability to focus on close objects that results in

      6/26/25 6:55:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

      PITTSBURGH, June 12, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to br

      6/12/25 4:30:00 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

      MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating Significant Chronic Night Driving Impairment in Keratorefractive Patients With Reduced Mesopic Vision, a Condition With No Current FDA-Approved Therapies No Evidence of Tachyphylaxis Was Observed In This Study Over The 6-Week Period Study Was Conducted Under FDA Special Protocol Assessment And Fast-Track Designation PITTSBURGH, June 2, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluati

      6/2/25 8:00:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Smith Scott Andrew bought $536,262 worth of shares (60,000 units at $8.94), increasing direct ownership by 26% to 292,807 units (SEC Form 4)

      4 - Viatris Inc (0001792044) (Issuer)

      5/14/25 6:00:11 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Damelio Frank A

      4 - Viatris Inc (0001792044) (Issuer)

      5/13/25 6:06:15 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Severino Michael

      4 - Viatris Inc (0001792044) (Issuer)

      5/13/25 6:04:29 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Smith Scott Andrew bought $536,262 worth of shares (60,000 units at $8.94), increasing direct ownership by 26% to 292,807 units (SEC Form 4)

      4 - Viatris Inc (0001792044) (Issuer)

      5/14/25 6:00:11 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

      4 - Viatris Inc (0001792044) (Issuer)

      10/25/24 4:30:03 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Viatris Inc.

      SCHEDULE 13G - Viatris Inc (0001792044) (Subject)

      5/14/25 10:45:26 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Viatris Inc.

      SCHEDULE 13G/A - Viatris Inc (0001792044) (Subject)

      5/8/25 10:20:37 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Viatris Inc.

      10-Q - Viatris Inc (0001792044) (Filer)

      5/8/25 9:21:14 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Viatris with a new price target

      Goldman initiated coverage of Viatris with a rating of Neutral and set a new price target of $10.00

      6/6/25 8:33:51 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Viatris with a new price target

      Jefferies resumed coverage of Viatris with a rating of Buy and set a new price target of $15.00

      7/19/24 8:34:32 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris downgraded by BofA Securities with a new price target

      BofA Securities downgraded Viatris from Neutral to Underperform and set a new price target of $9.00 from $13.00 previously

      10/23/23 7:20:20 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer

      PITTSBURGH, April 14, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team. Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and strategic transformations in diversified multi-national healthcare companies. Prior to joining Viatris, Varghese was President and Chief Operating Officer at Venu

      4/14/25 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors

      PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. "We are pleased to welcome Dr. Vivaldi to our Board of Directors," said Melina Higgins, Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Commit

      6/3/24 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Appoints Corinne Le Goff as Chief Commercial Officer

      PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific background and experience across multiple markets and therapeutic areas. Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology

      4/15/24 8:00:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Financials

    Live finance-specific insights

    See more
    • Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

      PITTSBURGH, June 12, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to br

      6/12/25 4:30:00 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook

      Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base BusinessMakes Significant Pipeline Progress With Three Positive Phase 3 Data Readouts Returns More Than $450 Million in Capital to Shareholders Year-to-Date and Reaffirms 2025 Capital Allocation Priorities PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1]. Executive Commentary "2025 is off to a good start as we continue to focus on executing our strategic priorities," said Scott A. Smith, CEO, Viatris. "Our growing pipeline, capital discipline, operational execution, and

      5/8/25 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Announces Quarterly Dividend

      PITTSBURGH, May 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on May 5, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 16, 2025, to shareholders of record as of the close of business on May 23, 2025.  About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare nee

      5/7/25 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Viatris Inc.

      SC 13G/A - Viatris Inc (0001792044) (Subject)

      11/12/24 1:41:20 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Viatris Inc. (Amendment)

      SC 13G/A - Viatris Inc (0001792044) (Subject)

      2/13/24 5:17:31 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Viatris Inc.

      SC 13G - Viatris Inc (0001792044) (Subject)

      2/9/24 1:10:51 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care